164 related articles for article (PubMed ID: 23904188)
1. A truncated-Flt1 isoform of breast cancer cells is upregulated by Notch and downregulated by retinoic acid.
Mezquita B; Mezquita J; Barrot C; Carvajal S; Pau M; Mezquita P; Mezquita C
J Cell Biochem; 2014 Jan; 115(1):52-61. PubMed ID: 23904188
[TBL] [Abstract][Full Text] [Related]
2. A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells.
Mezquita B; Mezquita J; Pau M; Mezquita C
J Cell Biochem; 2010 Jun; 110(3):732-42. PubMed ID: 20512933
[TBL] [Abstract][Full Text] [Related]
3. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
[TBL] [Abstract][Full Text] [Related]
4. A study on Notch signaling in human breast cancer.
Zang S; Ji Ch; Qu X; Dong X; Ma D; Ye J; Ma R; Dai J; Guo D
Neoplasma; 2007; 54(4):304-10. PubMed ID: 17822320
[TBL] [Abstract][Full Text] [Related]
5. Different expression levels of DLK1 inversely modulate the oncogenic potential of human MDA-MB-231 breast cancer cells through inhibition of NOTCH1 signaling.
Nueda ML; Naranjo AI; Baladrón V; Laborda J
FASEB J; 2017 Aug; 31(8):3484-3496. PubMed ID: 28461338
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function.
Williams CK; Li JL; Murga M; Harris AL; Tosato G
Blood; 2006 Feb; 107(3):931-9. PubMed ID: 16219802
[TBL] [Abstract][Full Text] [Related]
7. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.
Lee TH; Seng S; Sekine M; Hinton C; Fu Y; Avraham HK; Avraham S
PLoS Med; 2007 Jun; 4(6):e186. PubMed ID: 17550303
[TBL] [Abstract][Full Text] [Related]
9. Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells.
Portanova P; Notaro A; Pellerito O; Sabella S; Giuliano M; Calvaruso G
Int J Oncol; 2013 Jul; 43(1):121-30. PubMed ID: 23686163
[TBL] [Abstract][Full Text] [Related]
10. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.
Harrington LS; Sainson RC; Williams CK; Taylor JM; Shi W; Li JL; Harris AL
Microvasc Res; 2008 Mar; 75(2):144-54. PubMed ID: 17692341
[TBL] [Abstract][Full Text] [Related]
11. N-terminal cleavage and release of the ectodomain of Flt1 is mediated via ADAM10 and ADAM 17 and regulated by VEGFR2 and the Flt1 intracellular domain.
Raikwar NS; Liu KZ; Thomas CP
PLoS One; 2014; 9(11):e112794. PubMed ID: 25387128
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
Cohen B; Shimizu M; Izrailit J; Ng NF; Buchman Y; Pan JG; Dering J; Reedijk M
Breast Cancer Res Treat; 2010 Aug; 123(1):113-24. PubMed ID: 19915977
[TBL] [Abstract][Full Text] [Related]
13. Gamma-Secretase Inhibitor, DAPT, Prevents the Development of Retinopathy of Prematurity in a Rat Model by Regulating the Delta-Like Ligand 4/Notch Homolog-1 (DLL4/Notch-1) Pathway.
Sun W; Li J; Li Y; Zheng J; Zhang X; Huang X; Li S
Med Sci Monit; 2019 Jan; 25():492-499. PubMed ID: 30652694
[TBL] [Abstract][Full Text] [Related]
14. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.
Han J; Ma I; Hendzel MJ; Allalunis-Turner J
Breast Cancer Res; 2009; 11(4):R57. PubMed ID: 19660128
[TBL] [Abstract][Full Text] [Related]
15. Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo.
Naranjo AI; González-Gómez MJ; Baladrón V; Laborda J; Nueda ML
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163478
[TBL] [Abstract][Full Text] [Related]
16. Targeting of miR9/NOTCH1 interaction reduces metastatic behavior in triple-negative breast cancer.
Mohammadi-Yeganeh S; Mansouri A; Paryan M
Chem Biol Drug Des; 2015 Nov; 86(5):1185-91. PubMed ID: 25963903
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.
Su F; Zhu S; Ruan J; Muftuoglu Y; Zhang L; Yuan Q
Oncotarget; 2016 Jan; 7(4):4142-54. PubMed ID: 26716652
[TBL] [Abstract][Full Text] [Related]
18. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways.
Ahmad A; Wang Z; Kong D; Ali R; Ali S; Banerjee S; Sarkar FH
Breast Cancer Res Treat; 2011 Feb; 126(1):15-25. PubMed ID: 20379844
[TBL] [Abstract][Full Text] [Related]
19. Adrenergic signaling promotes angiogenesis through endothelial cell-tumor cell crosstalk.
Chen H; Liu D; Yang Z; Sun L; Deng Q; Yang S; Qian L; Guo L; Yu M; Hu M; Shi M; Guo N
Endocr Relat Cancer; 2014 Oct; 21(5):783-95. PubMed ID: 25179535
[TBL] [Abstract][Full Text] [Related]
20. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
